SLU-PP-332: The Exercise Mimetic That Programs Your Cells to Burn Fat and Build Endurance
Published: February 2026 | Read Time: 18-22 minutes
Your mitochondria are the engines that power every cell in your body. When they decline, everything declines. Energy crashes. Fat accumulates where it never used to. Recovery takes twice as long. Metabolic flexibility disappears, leaving your body stuck burning sugar instead of fat.
SLU-PP-332 addresses this at the root. It is a synthetic compound that activates the same nuclear receptors triggered by endurance exercise, telling your cells to build new mitochondria, increase fatty acid oxidation, and shift muscle fibers toward the endurance phenotype. In preclinical studies, a single week of treatment increased running endurance by roughly 70% and running distance by approximately 45% in sedentary mice. No training required.
This is not a stimulant. It does not artificially increase heart rate or suppress appetite. SLU-PP-332 reprograms cellular metabolism at the genetic level through estrogen-related receptor activation, producing the same adaptations that months of aerobic training create. For anyone dealing with metabolic dysfunction, mitochondrial decline, or the inability to exercise due to injury or disability, this compound represents a genuinely novel approach.
KEY FACTS
Definition: SLU-PP-332 is a synthetic pan-agonist of estrogen-related receptors (ERR-alpha, beta, and gamma) that mimics the cellular effects of endurance exercise
Primary Use: Mitochondrial biogenesis, fat oxidation enhancement, endurance improvement, and metabolic optimization
Administration: Oral capsules (most common consumer form) or injectable with DMSO carrier (clinical/practitioner preference)
Typical Timeline: Initial energy changes in 1-2 weeks, measurable body composition shifts by 4-8 weeks
Best For: Individuals with metabolic dysfunction, athletes seeking endurance enhancement, aging adults with mitochondrial decline, or those unable to exercise due to injury
Not For: Anyone expecting a replacement for all exercise benefits (SLU-PP-332 does not build structural strength, flexibility, or load-bearing bone density)
What Is SLU-PP-332?
SLU-PP-332 was developed at Washington University in St. Louis (hence the "SLU" in its name) as part of a decade-long effort to create compounds that activate estrogen-related receptors. Despite the name, these receptors have nothing to do with estrogen. ERRs are classified as "orphan" nuclear receptors because they were discovered without a known natural ligand. They regulate cellular energy metabolism, mitochondrial biogenesis, and oxidative capacity independently of any hormonal estrogen signaling.
There are three ERR isoforms. ERR-alpha is the primary target and the one most closely associated with exercise-induced metabolic adaptation. ERR-beta plays a supporting role in metabolic regulation. ERR-gamma is heavily involved in cardiac and muscle metabolism. SLU-PP-332 activates all three, with the strongest potency at ERR-alpha (EC50 of 98 nM), followed by ERR-beta (230 nM) and ERR-gamma (430 nM).
When ERR-alpha is activated, it recruits a co-activator protein called PGC-1-alpha, often described as the "master regulator" of mitochondrial biogenesis. This partnership drives the transcription of hundreds of genes involved in fatty acid oxidation, glucose metabolism, mitochondrial respiration, and muscle fiber type conversion. The result is that cells begin behaving as if their owner is consistently performing aerobic exercise.
A helpful way to understand this: think of ERR-alpha as a chief librarian who controls access to an entire catalog of metabolic instruction manuals. Without activation, those manuals sit on the shelf. Exercise naturally activates this librarian. SLU-PP-332 does the same thing pharmacologically, opening the same genetic programs without requiring physical exertion.
The Science: How SLU-PP-332 Works
The ERR-PGC-1-alpha Cascade
The mechanism follows a specific sequence. SLU-PP-332 binds to estrogen-related receptors. This binding stabilizes the receptor in its active conformation. The active receptor then recruits PGC-1-alpha as a co-activator. Together, they bind to DNA response elements and initiate transcription of metabolic genes. These genes encode proteins for mitochondrial assembly, fatty acid transport, electron transport chain components, and muscle fiber remodeling.
The downstream effects include increased mitochondrial DNA content (more mitochondria per cell), enhanced maximum mitochondrial respiratory capacity, upregulation of fatty acid oxidation enzymes like CPT1A and ACOX1, increased GLUT4 glucose transporter expression, and conversion of glycolytic (Type II) muscle fibers toward oxidative (Type IIa) fibers associated with endurance.
Mitochondrial Biogenesis vs. Mitochondrial Protection
This distinction matters for anyone building a mitochondrial optimization protocol. SLU-PP-332 is a builder. It creates new mitochondria and enhances existing mitochondrial function. It does not inherently protect mitochondrial membranes from oxidative damage.
This is where understanding the difference between SLU-PP-332 and compounds like SS-31 becomes critical. SS-31 (Elamipretide) stabilizes cardiolipin in the inner mitochondrial membrane, protecting existing mitochondria from electron leak and reactive oxygen species damage. It is a protector, not a builder.
Clinical experience suggests the ideal approach uses both strategically. SLU-PP-332 drives the creation of new mitochondria. SS-31 protects those new mitochondria from damage. Without the protector, aggressive mitochondrial biogenesis can lead to a phenomenon practitioners call "overspin," where the electron transport chain generates excessive reactive oxygen species because newly formed mitochondria lack adequate membrane stability.
The Overspin Problem
This is the most important safety concept with SLU-PP-332 and one that virtually no online guides discuss properly.
Every mitochondrion maintains a membrane potential between 150-200 millivolts. This voltage drives ATP synthesis through the electron transport chain. When mitochondrial biogenesis is pushed aggressively without adequate protective support, the newly formed mitochondria can "spin" too fast. Electrons leak from the transport chain. Protons escape. Reactive oxygen species production spikes.
The symptoms of overspin include: unexplained tachycardia (elevated resting heart rate), paradoxical fatigue despite using an "energy" compound, increased susceptibility to illness, feeling wired but exhausted simultaneously, and shortness of breath during activities that previously felt easy.
The solution is not to abandon SLU-PP-332 but to stack it properly. SS-31 provides membrane protection. Glutathione (injectable preferred, 200-400mg IM twice weekly) scavenges excess ROS. Urolithin A (500mg daily) drives mitophagy, recycling damaged mitochondria before they become problematic. This combination creates a complete mitochondrial optimization system rather than just pushing one pathway.
Research Evidence
Original Washington University Studies (2023)
The foundational research published in ACS Chemical Biology established SLU-PP-332 as the first synthetic compound capable of activating all three ERR isoforms with sufficient potency for in vivo use. In sedentary C57BL/6J mice treated for just 7 days with SLU-PP-332 (50 mg/kg, twice daily, intraperitoneal), running endurance increased by approximately 70% and running distance by roughly 45% compared to vehicle-treated controls. A two-week treatment protocol also demonstrated increased grip strength. The compound increased mitochondrial DNA content in skeletal muscle, confirming genuine mitochondrial biogenesis rather than just enhanced function of existing mitochondria. Muscle fiber analysis showed increased oxidative Type IIa fibers, the phenotype associated with endurance capacity.
Metabolic Syndrome Studies (2024)
Published in the Journal of Pharmacology and Experimental Therapeutics, this research tested SLU-PP-332 in diet-induced obese mice and ob/ob genetic obesity models. Treatment over 28 days at 50 mg/kg twice daily produced decreased fat mass accumulation, increased resting energy expenditure, enhanced fatty acid oxidation, improved glucose tolerance and insulin sensitivity, and reduced liver triglyceride content. The ob/ob mice (which have severe genetic obesity) showed similar improvements over a 12-day treatment window, with the shorter duration used due to reduced tolerance of repeated intraperitoneal injections in this model.
Heart Failure Research (Circulation, 2024)
Pan-ERR agonists including SLU-PP-332 and the newer SLU-PP-915 were tested in pressure-overload induced heart failure models. Both compounds significantly improved ejection fraction (how efficiently the heart pumps), reduced cardiac fibrosis, and increased survival rates. The mechanism operated primarily through ERR-gamma activation, which enhanced cardiac fatty acid metabolism and mitochondrial function. This research is significant because it demonstrates SLU-PP-332 benefits extend beyond skeletal muscle to cardiac tissue.
Aging Kidney Reversal (American Journal of Pathology, 2023)
In 21-month-old mice (roughly equivalent to elderly humans), 8 weeks of pan-ERR agonist treatment reversed age-related increases in albuminuria (protein in urine, a marker of kidney damage), podocyte loss, mitochondrial dysfunction, and inflammatory cytokines in kidney tissue. The effects were comparable to lifelong caloric restriction, one of the most well-established longevity interventions.
Anti-Sarcopenia Pilot Study (Frontiers in Physiology, 2025)
This is the most clinically relevant study to date. Researchers at Policlinico Tor Vergata in Italy took muscle biopsies from 20 elderly women undergoing hip replacement surgery, divided into active and inactive groups. They then treated primary myoblast cultures from inactive women with SLU-PP-332. The treatment downregulated NOX4 (a source of oxidative stress), upregulated SIRT1, PGC-1-alpha, ERR-alpha, FNDC5, Akt, and Bcl-2. It reduced cytotoxicity by 16%, oxidative stress by 38%, and cellular senescence by 26%, while increasing intracellular glutathione by 117%. SLU-PP-332 also promoted abundant myotube formation, demonstrating its ability to drive muscle cell differentiation even in aged, sedentary-derived tissue. While still an ex vivo study (cells treated in a dish, not humans taking the compound), this represents the first use of human-derived tissue.
COVID-19 Hypothesis (Medical Hypotheses, 2024)
A theoretical paper proposed SLU-PP-332 as a potential prophylactic against severe COVID-19, based on its ability to inhibit ACE2 expression, stimulate immune function, suppress pro-inflammatory cytokines, and reduce viral entry points in adipose tissue through FNDC5 upregulation. While speculative, this aligns with the broader understanding that mitochondrial fitness correlates with immune resilience.
Practical Protocols
Administration Routes
There is an important debate in the practitioner community about oral versus injectable administration. The original research used intraperitoneal injection in mice. Most consumer products are sold as oral capsules, typically 250mcg per capsule.
Some practitioners argue that SLU-PP-332 requires a DMSO carrier for proper absorption when injected, and that oral bioavailability is limited. Others report clinical success with oral dosing at appropriate levels. The published pharmacokinetic data shows that SLU-PP-332 achieves plasma exposure of 0.2 micromolar and muscle exposure of 0.6 micromolar at 6 hours post-injection (30 mg/kg IP) in mice.
For practical purposes, most people in the biohacking community use oral capsules, and anecdotal reports suggest meaningful effects at the dosing ranges below.
Dosing Tiers
Conservative start (weeks 1-2): 100-250 mcg daily, taken in the morning or pre-workout. This allows assessment of individual tolerance and identifies any sensitivity to mitochondrial activation.
Standard protocol (weeks 3-8): 250-500 mcg daily. Most users settle in this range. Some practitioners suggest taking it only on training days when exercise synergy is the goal, as SLU-PP-332 produces additive effects when combined with actual exercise.
Advanced protocol (weeks 8-12): 500-750 mcg daily, sometimes split into two doses (morning and pre-workout). This range is typically used by experienced biohackers who have confirmed tolerance and are running concurrent protective compounds like SS-31 and glutathione.
Practitioner-guided range: Up to 1mg daily in specific clinical contexts, always with protective stacking.
Timing Considerations
SLU-PP-332 is energizing. It activates metabolic gene programs that increase cellular energy production. Taking it late in the day can interfere with sleep. Morning dosing or pre-workout timing (at least 6-8 hours before bed) is recommended.
On training days, dosing 30-60 minutes before exercise appears to produce additive effects. The original mouse research confirmed that SLU-PP-332 combined with exercise produced greater gene expression changes than either intervention alone.
Cycle Length
Unlike many peptides that require cycling to prevent receptor desensitization, ERR agonists do not appear to cause downregulation with continuous use based on current evidence. Most protocols run 8-12 weeks followed by a 2-4 week assessment period. Some practitioners recommend continuous use at lower maintenance doses after the initial protocol.
PROTOCOL SUMMARY (TEXT): Typical dosing ranges from 100 mcg to 750 mcg daily, taken orally in the morning or pre-workout. Most users begin at 100-250 mcg for the first two weeks, increase to 250-500 mcg for weeks 3-8, and may progress to 500-750 mcg for weeks 8-12 if running concurrent protective compounds. Always start conservative and assess tolerance before increasing.
What to Expect
Week 1-2: Subtle energy improvements. Many users report feeling "cleaner" energy without the jittery quality of stimulants. Slight increase in workout endurance may be noticeable. Some people feel nothing initially. This does not mean the compound is not working. Mitochondrial biogenesis is a gradual genomic process, not an acute pharmacological effect.
Week 3-4: More consistent energy throughout the day. Fat utilization during exercise may improve, noticeable as the ability to sustain moderate-intensity work for longer periods. Sleep quality may improve if dosing is timed correctly (morning). Some users report reduced muscle soreness after training sessions.
Week 5-8: This is where measurable changes typically appear. Body composition shifts become visible in people with adequate protein intake and training stimulus. Endurance capacity shows meaningful improvement. Fasting glucose and insulin sensitivity may improve (worth tracking with bloodwork). Resting heart rate may decrease slightly as cardiovascular efficiency improves.
Week 9-12: Cumulative mitochondrial biogenesis reaches its peak effect window. The difference in exercise capacity compared to baseline is most apparent. If stacked with SS-31 and other mitochondrial protectors, users report a qualitative shift in metabolic flexibility, feeling equally comfortable burning fat or carbohydrates depending on activity demands.
Advanced Stacking Strategies
Stack 1: The Complete Mitochondrial Protocol
SLU-PP-332 (250-500 mcg daily, oral, AM) + SS-31 (1-5 mg subcutaneous, 2-3x weekly) + Urolithin A (500 mg daily, oral) + NAD+ precursor or injectable NAD+ (variable dosing)
This is the comprehensive approach. SLU-PP-332 builds new mitochondria. SS-31 protects their membranes. Urolithin A recycles damaged ones through mitophagy. NAD+ supports the coenzyme that mitochondria require for electron transport. Each compound addresses a different aspect of mitochondrial health.
Important sequencing note: Start SS-31 first for 2-4 weeks before adding SLU-PP-332. This establishes a protective foundation before pushing biogenesis. Adding SLU-PP-332 without prior membrane protection increases the risk of overspin.
Stack 2: The Endurance Athlete Stack
SLU-PP-332 (250-500 mcg on training days) + injectable L-Carnitine (200mg-1g, 3-5x weekly) + 5-Amino-1MQ (50-100 mg daily, oral)
L-Carnitine shuttles fatty acids into mitochondria for oxidation. SLU-PP-332 creates more mitochondria to receive those fatty acids. 5-Amino-1MQ inhibits NNMT, reducing fat storage and improving metabolic efficiency. This stack targets endurance performance and body recomposition simultaneously.
Stack 3: The BAM-15 Synergy Stack
SLU-PP-332 (250 mcg daily) + BAM-15 (capsule form, per label dosing)
BAM-15 is a mitochondrial uncoupler that dissipates the proton gradient as heat rather than ATP. When combined with SLU-PP-332 at a ratio that practitioners suggest is roughly 2:1 (BAM-15 to SLU-PP-332 by effect), you create controlled "productive inefficiency." The new mitochondria SLU-PP-332 builds are partially uncoupled by BAM-15, generating heat and burning calories without producing excessive ROS. This is a potent fat loss combination.
Stack 4: The Anti-Aging Foundation
SLU-PP-332 (100-250 mcg daily) + MOTS-c (5-10 mg subcutaneous, 3x weekly) + Epithalon (5-10 mg subcutaneous, cycling 10 days on, 10 days off)
For longevity-focused protocols, lower-dose SLU-PP-332 provides ongoing mitochondrial renewal. MOTS-c is a mitochondrial-derived peptide that improves insulin sensitivity and activates AMPK. Epithalon supports telomere maintenance. This stack addresses multiple aging pathways simultaneously at conservative doses.
Stack 5: The Metabolic Rescue Stack
SLU-PP-332 (250 mcg daily, titrate up) + Tesofensine (250-500 mcg daily, oral) + Glutathione (200-400 mg IM, 2x weekly)
For individuals with significant metabolic dysfunction, insulin resistance, or obesity. SLU-PP-332 restores mitochondrial capacity. Tesofensine acts as a triple reuptake inhibitor that suppresses appetite and increases energy expenditure through central mechanisms. Glutathione provides antioxidant protection against the increased oxidative demands of metabolic restoration. This is not a first-line approach. It requires monitoring and ideally practitioner guidance.
Safety and Side Effects
Known Considerations
SLU-PP-332 has no published human safety data. All evidence comes from murine models and ex vivo human cell studies. This is a critical caveat that must inform any decision to use this compound.
In animal studies, SLU-PP-332 did not produce significant adverse effects at therapeutic doses over 28-day treatment periods. Liver enzymes (ALT/AST) remained stable. Blood lipid profiles were unchanged or improved. No cardiac hypertrophy was observed even in heart failure models where ejection fraction improved.
Theoretical Concerns
Pan-ERR activation: Because SLU-PP-332 activates all three ERR isoforms, there is theoretical concern about off-target effects in tissues where specific isoforms should remain at baseline activity. The development of more selective next-generation compounds (by the same research group, through Pelagos Pharmaceuticals) aims to address this.
Cardiac considerations: While the heart failure research showed benefit, ERR-gamma activation at very high levels could theoretically promote cardiac remodeling. Anyone with existing cardiac conditions should approach with caution.
Mitochondrial overspin: As discussed above, aggressive dosing without protective co-factors (SS-31, glutathione, Urolithin A) can lead to excessive ROS production with symptoms of tachycardia, paradoxical fatigue, and immune suppression.
Contraindications
Active cancer (ERR activation may influence cell proliferation pathways; evidence is mixed and context-dependent)
Pregnancy or breastfeeding (no safety data)
Severe liver disease (primary metabolic organ for this compound)
Concurrent use of drugs metabolized by CYP450 pathways (potential interactions unknown)
Hyperthyroidism or uncontrolled thyroid conditions (increased metabolic drive could worsen symptoms)
Monitoring Recommendations
Before starting: comprehensive metabolic panel, lipid panel, fasting glucose, HbA1c, TSH, complete blood count. Repeat at 8-12 weeks. Track resting heart rate weekly. Monitor subjective energy, recovery, and any symptoms of overspin.
Trusted Sources
Quality matters with research compounds, and SLU-PP-332 is expensive to synthesize properly. Third-party testing and legitimate Certificates of Analysis are non-negotiable. Suspiciously cheap pricing is a red flag.
Vetted suppliers with COAs:
Modern Aminos - Code: zach10 (10% off)
Optimum Formula - Code: BHACK (10% off)
ResearchChemHQ - Code: BHACK
LimitlessBioChem EU - Code: BHACK (10% off)
Limitless Life Nootropics - Code: BHACK (15% off)
For complete vendor comparison: biohackblueprint.io
The Bigger Picture: Exercise Mimetics and Mitochondrial Medicine
SLU-PP-332 represents a shift in how we think about metabolic health. Conventional approaches treat symptoms downstream. Diabetes gets insulin. Heart failure gets diuretics. Obesity gets appetite suppressants. These interventions manage consequences without addressing the cellular energy crisis that drives them.
Mitochondrial medicine addresses the source. When cells cannot produce adequate ATP, everything downstream breaks. Insulin signaling fails because the energy-dependent GLUT4 translocation cannot occur efficiently. Cardiac output drops because cardiomyocytes lack the fuel to contract. Fat accumulates because the oxidative machinery that burns it has deteriorated.
SLU-PP-332, alongside compounds like SS-31, MOTS-c, and NAD+ precursors, belongs to a new category that targets the root cause rather than the symptoms. The research group that developed it has already created next-generation compounds through Pelagos Pharmaceuticals with improved potency, better selectivity, and the ability to cross the blood-brain barrier for neurodegenerative applications.
For the biohacking community, the practical takeaway is that mitochondrial optimization is not about any single compound. It requires a systems approach: building new mitochondria (SLU-PP-332), protecting existing ones (SS-31), recycling damaged ones (Urolithin A), and supplying the raw materials they need (NAD+, L-Carnitine). Understanding how these pieces fit together is what separates effective protocols from random supplementation.
Frequently Asked Questions
Does SLU-PP-332 have estrogenic effects? No. Despite the name "estrogen-related receptor," ERRs are orphan nuclear receptors that operate independently of estrogen signaling. SLU-PP-332 does not bind classical estrogen receptors (ER-alpha or ER-beta) and produces zero hormonal estrogenic effects. It will not cause gynecomastia, water retention, or any estrogen-related side effects.
Can SLU-PP-332 replace exercise entirely? No. SLU-PP-332 replicates the mitochondrial and metabolic adaptations of endurance exercise. It does not replace the structural benefits: bone density from load-bearing activity, connective tissue strengthening, neuromuscular coordination, flexibility, or the psychological benefits of physical movement. It is best understood as a complement to exercise, not a replacement. For those who genuinely cannot exercise, it provides metabolic benefits that would otherwise be inaccessible.
What is the difference between SLU-PP-332 and GW-501516 (Cardarine)? GW-501516 is a PPAR-delta agonist. SLU-PP-332 is an ERR agonist. Both enhance endurance and fat oxidation, but through different nuclear receptor pathways. GW-501516 carries documented cancer risk from preclinical studies (tumor promotion in multiple organs). SLU-PP-332 has not shown similar carcinogenic signals in published research. They target overlapping but distinct gene programs, and some practitioners have used them in combination, though this increases complexity and risk.
Should I take SLU-PP-332 on rest days? This depends on your goals. For metabolic and longevity applications, daily dosing maintains consistent ERR activation. For performance-focused protocols, some practitioners recommend training-day-only dosing because the additive effect with exercise produces the strongest gene expression response. Both approaches are used in practice.
How does SLU-PP-332 interact with GLP-1 agonists? SLU-PP-332 and GLP-1 receptor agonists (semaglutide, tirzepatide, retatrutide) target completely different pathways. GLP-1 agonists work through appetite suppression and insulin signaling. SLU-PP-332 works through mitochondrial biogenesis and fatty acid oxidation. They are mechanistically complementary. The concern with GLP-1 agonists is muscle loss alongside fat loss. SLU-PP-332 may partially offset this by maintaining mitochondrial function and promoting muscle fiber quality, though this has not been directly studied.
Final Thoughts
SLU-PP-332 occupies a unique position in the research compound landscape. It is not a peptide in the traditional sense but a small molecule that activates nuclear receptors controlling some of the most fundamental aspects of cellular metabolism. The published research is compelling. The preclinical data spans exercise capacity, metabolic syndrome, heart failure, kidney aging, and now human-derived muscle tissue. The development of next-generation compounds by the same research team suggests institutional confidence in the ERR agonist approach.
The absence of human clinical trials remains the most significant limitation. Everything we know about dosing, timing, and side effects in humans comes from extrapolation and anecdotal community experience. This makes conservative dosing, proper protective stacking, and baseline bloodwork monitoring essential rather than optional.
For those who choose to explore this compound, the difference between success and problems comes down to understanding the overspin concept and building a complete mitochondrial protocol rather than treating SLU-PP-332 as a standalone solution. Build, protect, recycle, and supply. That is the framework.
Disclaimer: This content is for educational and research purposes only. Peptides are not approved for human use. Nothing here is medical advice. Consult a qualified professional for personalized guidance.
